Teva Presents Update On Strategic Plan

The growing demand for generic pharmaceuticals as a means to expand access to affordable high-quality medicine and control healthcare costs will continue to drive the growth of the company’s core business in the US and globally. A portion of this growth is expected to come from those European and international markets that are currently characterized by low generic penetration rates.

The branded business will be further strengthened through internal R&D, licensing and other business development opportunities, and geographic expansion of its existing product portfolio thereby enhancing its balanced business model. Biogenerics is another important growth driver in future of the company, said the company.

The growth will be driven by its market leadership and competitive advantages, including its scale and global footprint, its high degree of back integration, the robustness of its product portfolio and track record in being first to market in the US and other regions and its commitment to high quality. With these competitive advantages, Teva will seek to outpace market growth.

Shlomo Yanai, president and CEO Teva, said: “In the years to come, Teva will seek to extend our global leadership and deliver profitable growth, doubling our revenues by 2015 and reaching net income margins of 22%. Our core business, generics, will continue to drive our growth.

“At the same time, we will continue to expand our branded business, further leveraging the diversity of our balanced business model.All of us at Teva are enthusiastic about what we plan to achieve in the next five years, and in particular about the value we expect to create for all of our stakeholders.”